Part 1: The Future of Knowledge, the Knowledge Graph

Summary (TL;DR)

• Interfaces (chatbots, prompts) are not the knowledge itself.

• Provide Credibility: visual, citable evidence first.

• Agentic tools make citations and reports faster.

Introduction & Background of the Knowledge Graph(KG)

A knowledge graph models a domain as nodes and edges, for example, in our GMP and Life science world, an example may be firms, facilities, products, and those product disclosures and distributors.

From Tech to GMP Quality Instance

Bringing the world of technical advancement and modern tech tooling into the grounded and intricate world of regulatory compliance and Good Manufacturing Practice (GMP) data requires added steps of verification and validation, careful handling of terminology and SOP context, and strict provenance to keep conclusions defensible. As a simple micro example, the GKS knowledge graph can link an FDA investigator’s observations recorded on a Form FDA 483 to a subsequent FDA Warning Letter, allowing analysts to verify the path from observation to citation to enforcement.

Introducing the example posed above, GKS has launched the new knowledge graph feature that enables not only end-to-end traceability but also connectivity between related events. Consider a case study: you are researching a particular firm, such as the recent Glenmark Pharmaceuticals Warning Letter (July 11, 2025). It quickly becomes apparent that understanding linkages between Form FDA-483 observations and subsequent Warning Letter citations—together with the firm’s prior inspections and enforcement actions is essential for context.

Within the graph, an Inspection instance (e.g., the Glenmark inspection) is represented as a first‑class node connected to the explicit documented events,the WL and 483, as well as to Person/Official nodes with explicit roles (investigator, compliance officer, signatory authority).

By grounding such questions in a typed graph with provenance-rich edges, the system returns an auditable answer, along with links to the underlying FDA documents.

Conclusion

The Glenmark case illustrates how a provenance-rich knowledge graph converts unstructured FDA artifacts into a unified, auditable workflow with executive-level metrics. Instead of spending 15–30 minutes per session searching scattered FDA sources, analysts can verify and resolve queries in a single step. This same capability also enhances compliance intelligence by enabling more effective supplier audit responses, informed supplier selection, and other applications that benefit from structured, verifiable intelligence.

When a KG-powered workflow supports internal products, deviations, and knowledge management, the organization and most critically the people behind it can focus on the core mission of our industry: bringing and maintaining safe, effective drugs and devices to market.

“…downstream regulatory shocks have significant impacts on upstream innovation.”¹

By embedding these capabilities within both platform- and research-based layers, the GKS knowledge graph delivers measurable gains, transforming scattered, manual searching into a structured, verifiable, and scalable compliance workflow, helping eliminate regulatory shocks.

This article is a light version and serves as Part 1 , for the full whitepaper, please reach out: hello@globalkeysolutions.net